# A Study of Recombinant Human Growth Hormone Injection（JINTOPIN AQ）for Short Children With Small for SGA

> **NCT03221933** · PHASE2 · COMPLETED · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 120 (actual)

## Conditions studied

- Small for Gestational Age Infant

## Interventions

- **BIOLOGICAL:** Somatropin Injection low dose group
- **BIOLOGICAL:** Somatropin Injection high dose group

## Key facts

- **NCT ID:** NCT03221933
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2014-12
- **Final completion:** —
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2017-12-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03221933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03221933, "A Study of Recombinant Human Growth Hormone Injection（JINTOPIN AQ）for Short Children With Small for SGA". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03221933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*